News
Why We Invested: Lumata Health
Check out our latest “Why We Invested” blog
Nathaniel Harding: Year in Review and 2024 Outlook
Let’s look back at 2023 for VC and our firm to set the stage for an exciting 2024
Cortado Ventures Doubleshot Newsletter: January 2024
MidCon Markup, CorriXR, Nathaniel Harding, and more
Cortado Ventures Invests in CorriXR
Cortado Ventures Invests in CorriXR
Nathaniel Harding’s Ongoing Board Commitment
Nathaniel Harding renews commitment to OKC Chamber
Cadenza Bio, Inc. Secures $2.44M in Oversubscribed Series Seed Financing
Preclinical...
GeoMark Research and Senslytics Forge Strategic Partnership to Pioneer Breakthroughs in Artificial Intelligence Solutions
For media inquiries,...
Nathaniel Harding featured on podcasts
Our managing partner, Nathaniel Harding has been featured on four podcasts
Cortado Ventures Doubleshot Newsletter: November 2023
Global Entrepreneurship Week, TIME’s Best Inventions of 2023, Fund II Celebration and more
nSight Surgical Honored with Surgical Transformation award
nSight Surgical for receives Best in Class for Surgical Transformation award
TIME Magazine Honors NuView & Pipedream: Best Inventions
TIME Magazine has named NUVIEW & Pipedream Labs as two of the best inventions of the year!
Why We Invested: Moat Biotechnology
Our General Partner Mike Moradi articulates our commitment to Moat Biotechnology.
Cortado Ventures Doubleshot Newsletter: October 2023
NW Arkansas Tech Summit, MidCon Markup Podcast, Fund Announcement, and much more
Cortado Ventures Invests in Teren, Inc.: Advancing Data-Driven Solutions for Climate and Terrain Risk Assessment
FOR IMMEDIATE RELEASE...
Cortado Ventures Receives National News Coverage
AltAssets: Hefty...
CORTADO VENTURES